Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Galapagos NV is a biotechnology company focused on the discovery and development of innovative medicines, primarily in the areas of immunology and oncology. The company operates within the global biopharmaceutical industry and is centered on research-driven drug development rather than large-scale commercial sales. Its activities have historically emphasized small-molecule therapies and, more recently, advanced cell therapy approaches. Galapagos’ primary value drivers are its proprietary research platforms, clinical-stage pipeline, and strategic capital deployment.
Founded in 1999, Galapagos evolved from a target-discovery-focused biotech into a late-stage clinical development company through internal R&D and partnerships. A long-standing global collaboration with Gilead Sciences significantly shaped its growth and balance sheet. Following mixed clinical and regulatory outcomes for its lead immunology asset filgotinib, the company initiated a strategic reset beginning in 2022, redirecting resources toward oncology and next-generation cell therapies while restructuring its operating model.
Business Operations
Galapagos operates primarily as a research and development organization, with business activities structured around drug discovery, preclinical research, and clinical development. The company does not currently operate a broad commercial pharmaceutical sales platform, and revenue generation has been limited following the restructuring of prior commercialization arrangements. Its operations are focused on advancing internally developed programs and assets obtained through acquisitions.
The company controls proprietary drug discovery technologies and cell therapy development capabilities, supported by subsidiaries including CellPoint and AboundBio. Galapagos conducts research internally and through controlled subsidiaries, while selectively partnering for manufacturing and specialized development activities. Its operations span both Europe and the United States, with clinical trials conducted internationally.
Strategic Position & Investments
Galapagos’ strategic direction emphasizes building a transformational oncology pipeline, particularly in cell therapies that aim to improve speed, flexibility, and patient access compared to traditional autologous approaches. A key pillar of this strategy is its investment in decentralized and point-of-care manufacturing models, which the company views as a potential competitive advantage in cell therapy delivery.
Major strategic investments include the acquisitions of CellPoint and AboundBio, which together form the foundation of Galapagos’ oncology cell therapy platform. The company maintains a strong cash position relative to its operating scale, enabling continued investment in R&D while absorbing clinical risk. Outside of oncology, Galapagos maintains a reduced but ongoing presence in immunology research, though this is no longer its primary strategic focus.
Geographic Footprint
Galapagos is headquartered in Belgium, with its principal offices in Mechelen. The company maintains a significant operational presence in Europe and the United States, reflecting its dual focus on European research roots and access to U.S.-based biotechnology talent and clinical infrastructure.
Its research, development, and clinical activities extend across North America and Europe, with international clinical trial sites supporting its pipeline. Through its subsidiaries and investments, Galapagos has expanded its operational influence in key global biotechnology hubs, particularly in U.S. oncology research centers.
Leadership & Governance
Galapagos is led by an executive team with deep experience in global pharmaceuticals, biotechnology R&D, and corporate strategy. The company’s leadership emphasizes scientific innovation, disciplined capital allocation, and long-term value creation following its strategic transformation.
- Paul Stoffels – Chief Executive Officer
- Bart Filius – Chief Financial Officer
- Piet Wigerinck – Chief Scientific Officer
- Christian Schade – Chief Business Officer
- Hans Clevers – Head of Research & Development
The company was founded by Onno van de Stolpe, who played a central role in shaping its early scientific culture and growth before stepping down from executive leadership. The current governance framework reflects a shift toward oncology-focused innovation and operational flexibility aligned with the company’s revised strategic vision.